All News

PSA068.jpg

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

d Jack Cush, MD

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients.

Read Article
RheumNow Podcast square

One in Ten is Bad! (5.12.2023)

d Jack Cush, MD

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

Read Article
TB.EMimage.CDC_.jpg

2022 EULAR Recommendations on Screening and Prophylaxis for Opportunistic Infections

d Jack Cush, MD

Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised.

Read Article
Clot.DVT_.VTE_.blood_.jpg

Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis

d Jack Cush, MD

A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).

Read Article
Tuesday Night Rheumatology: POD 3: Vasculitis: Evolution and Advances This webinar will feature highlights from these lectures followed by live audience Q & A: -New Therapies for PMR & GCA -Assessment of GCA and PMR -GPA Treatment Choices https://t.co/PRj6QQnxIS https://t.co/Y4aCyTrg0Z

Links:

Dr. John Cush RheumNow ( View Tweet)
One in Ten has Autoimmune Disease A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals. https://t.co/a2VbAO0Fc6 https://t.co/69Yl9OTtKY

Links:

Dr. John Cush RheumNow ( View Tweet)
Does King Charles have Sausage Digits (dactylitis) or OA? https://t.co/Wg3JaTAGf1 https://t.co/Wg3JaTAGf1 https://t.co/iAHfYbZD7t

Links:

Dr. John Cush RheumNow ( View Tweet)
REMIT-UC: Tofacitinib study 334 w/ Ulcerative Colitis:Clinical remission in 35%, Endoscopic remission in ~24%; & low risk (per/100PY) of serious infections (2.1), H zoster (0.5), & VTE (1.1). Loss of response in 45%, but recaptured 55% w/ dose escalation https://t.co/KgSrKBbv40 https://t.co/M74l4tOA3U

Links:

Dr. John Cush RheumNow ( View Tweet)
Heart to Heart: Cardiovascular Risk in RA Tune in to hear experts discuss cardiovascular risk assessment, patient education, and the importance of disease control in the latest therapeutic update sponsored by AbbVie US Medical Affairs. https://t.co/Tz8VBiXhwt https://t.co/EQ0dRmM27r

Links:

Dr. John Cush RheumNow ( View Tweet)
When Hannah Glick receives her M.D. this week, she will join her mother, Dr. Rachel Glick, and grandmother, Dr. Marilyn Heins, as the only family in the U.S. with three generations of women doctors that are living, according to @AAMCtoday. https://t.co/AzRw2I4CU8 #GoBlueMed https://t.co/0tgMwVLwxF

Links:

University of Michigan Medical School UMichMedSchool ( View Tweet)
View an interactive disease modification patient journey from the #LupusEducatorsNetwork and learn about the importance of helping to prevent renal damage in your patients with #LupusNephritis. #SponsoredbyGSKUSMA https://t.co/XKG25eVSfa https://t.co/Jbo2iR6OuJ

Links:

Dr. John Cush RheumNow ( View Tweet)
2010 Colchicine Price Hikes Adversely Affected Gout Care Research shows that the large increase in colchicine cost in 2010 was associated with an immediate decrease in colchicine prescription use,. https://t.co/WS721SlM6p https://t.co/BBdqDVGolq

Links:

Dr. John Cush RheumNow ( View Tweet)

Orphan drugs target rare dz <200k. New drugs (2008-2016) compared 5 yr sales 86 orphan Rx to 232 non-orphan = similar sales- Orphan ($719 mill) vs nonorphan ($812 mill). But orphan Rx lower volume offset by higher prices (7X higher) than nonorphan drugs https://t.co/I8kb4A0eyG https://t.co/gEQpssRVkg

Links:

Dr. John Cush RheumNow ( View Tweet)
May 16th--Tuesday Night Rheumatology: POD 3: Vasculitis: Evolution and Advances This webinar will feature highlights from these lectures followed by live audience Q & A: -New Therapies for PMR & GCA -Assessment of GCA and PMR -GPA Treatment Choices https://t.co/fphj3seU3K https://t.co/GSL41UZZ2Y

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy in PsA RheumNow Live 2023: Christina Chambers, PhD, MPH, University of California, San Diego School of Medicine https://t.co/ImgAwCvawE https://t.co/9GCZ1tBmkV

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 6039 NHL hockey players showed mortality rates were similar between fighters & controls (3.9% v4.2%) & Penalized vs not (7.1.% v 5.5%). Yet controls lived (~56yrs) avg of 10 yrs longer than fighters/penalized (~46yrs) w/ more suicide & overdose https://t.co/EKOeEKSejN https://t.co/7Axpz0QibY

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in Psoriasis and PsA RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine https://t.co/OV4rRR6eCh https://t.co/uY9MnwGveV

Links:

Dr. John Cush RheumNow ( View Tweet)
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported. https://t.co/SPmdBJ8IFh https://t.co/ad2j6XaSkK

Links:

Dr. John Cush RheumNow ( View Tweet)
Did you miss Tuesday Night Rheumatology this week? This webinar features highlights from: Preclinical RA – To Treat or Not To Treat Year of the JAKi Fibroblast/Stromal Cells https://t.co/yVQLtG6fEe https://t.co/WMXcKdqwdP

Links:

Dr. John Cush RheumNow ( View Tweet)
Another NHANES survey of US adults shows increased prevalence of RA for those exposed to high levels of polycyclic aromatic hydrocarbons (PAH)(OR: 1.8; p=0.02). 90% of the smoking effect on RA risk is mediated by PAH https://t.co/N93MbKspRM https://t.co/uqH75vOZrA

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×